Brought to you by 
Civitas chooses $525mm acquisition by Acorda over IPO
25 Aug 2020
Executive Summary
Acorda Therapeutics Inc. (neuromuscular and cardiovascular diseases) paid $525mm in cash for private drug delivery company Civitas Therapeutics Inc., which has abandoned its plans to go public (the company filed an S-1 in August). The purchase price includes $35mm tied to a Civitas change-in-control provision.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Civitas chooses $525mm acquisition by Acorda over IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice